Key facts
- It has raised $1.2M; the latest was Seed Round ($1.2M) in Oct 2025.
- Notable investors include Mythos Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ashlins Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Ashlins Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ashlins Pharmaceuticals
Operator of a biopharmaceutical company designed for patients to access rare disease treatments. The company provides biopharmaceutical medicines by drug repurposing, including an off-label use database and using a contribution-based compensation system, enabling rare disease patients to gain access to treatments faster by reducing the overall time and expense required for traditional drug development.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2025
- Website
- ashlinspharma.com/
- Ownership
- Privately Held (backing)
Ashlins Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ashlins Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ashlins Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.